LANSOPRAZOLE | A203203 | XIROMED PHARMA ESPANA SL
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Alembic Pharmaceuticals Limited FDA-2025-P-1021 · 5 docket documents Alembic Pharmaceuticals Limited filed this citizen petition requesting that the FDA determine whether Epinephrine Injection USP 1 mg/mL pre-filled syringe NDA 203203 was voluntarily withdrawn from sale for reasons related to safety or effectiveness. The petitioner seeks an FDA determination under 21 | 505(q) | 2025-03-31 | Granted | Alembic Pharmaceuticals Limited |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.1067
per ea
Lowest NADAC/Unit
$0.1067
per ea
Brand NDCs
0
Generic NDCs
3
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 70700026305LANSOPRAZOLE DR 30 MG CAPSULE | $0.1067 | EA | Generic | — | 2026-06-17 |
| 70700026330LANSOPRAZOLE DR 30 MG CAPSULE | $0.1067 | EA | Generic | — | 2026-06-17 |
| 70700026390LANSOPRAZOLE DR 30 MG CAPSULE | $0.1067 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.